Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs. Novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart

Carlo G Tocchetti* (Corresponding Author), Pietro Ameri, Rudolf A de Boer, Yuri D'Alessandra, Michele Russo, Daniela Sorriento, Michele Ciccarelli, Bernadett Kiss, Luc Bertrand, Dana Dawson, Ines Falcao-Pires, Mauro Giacca, Nazha Hamdani, Wolfgang A Linke, Manuel Mayr, Jolanda van der Velden, Serena Zacchigna, Alessandra Ghigo, Emilio Hirsch, Alexander R LyonAnikó Görbe, Péter Ferdinandy, Rosalinda Madonna, Stephane Heymans, Thomas Thum

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In western countries, cardiovascular (CV) disease and cancer are the leading causes of death in the ageing population. Recent epidemiological data suggest that cancer is more frequent in patients with prevalent or incident CV disease, in particular, heart failure (HF). Indeed, there is a tight link in terms of shared risk factors and mechanisms between HF and cancer. HF induced by anticancer therapies has been extensively studied, primarily focusing on the toxic effects that anti-tumour treatments exert on cardiomyocytes. In this Cardio-Oncology update, members of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart discuss novel evidence interconnecting cardiac dysfunction and cancer via pathways in which cardiomyocytes may be involved but are not central. In particular, the multiple roles of cardiac stromal cells (endothelial cells and fibroblasts) and inflammatory cells are highlighted. Also, the gut microbiota is depicted as a new player at the crossroads between HF and cancer. Finally, the role of non-coding RNAs in Cardio-Oncology is also addressed. All these insights are expected to fuel additional research efforts in the field of Cardio-Oncology.

Original languageEnglish
Pages (from-to)1820-1834
Number of pages14
JournalCardiovascular Research
Volume116
Issue number11
Early online date19 Jul 2020
DOIs
Publication statusPublished - 1 Sep 2020

Keywords

  • Cardio-Oncology
  • Common pathways in heart failure and cancer
  • Multicellular an multiorgan mechanisms
  • Multicellular and multiorgan mechanisms
  • DOXORUBICIN-INDUCED CARDIOTOXICITY
  • IMMUNE CHECKPOINT INHIBITORS
  • INFLAMMATORY RESPONSES
  • PRESERVED EJECTION FRACTION
  • EUROPEAN-SOCIETY
  • LUNG-CANCER
  • CHAIN FATTY-ACIDS
  • CLONAL HEMATOPOIESIS
  • CARDIOVASCULAR-DISEASE
  • HISTONE DEACETYLASE

Fingerprint Dive into the research topics of 'Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs. Novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart'. Together they form a unique fingerprint.

  • Cite this

    Tocchetti, C. G., Ameri, P., de Boer, R. A., D'Alessandra, Y., Russo, M., Sorriento, D., Ciccarelli, M., Kiss, B., Bertrand, L., Dawson, D., Falcao-Pires, I., Giacca, M., Hamdani, N., Linke, W. A., Mayr, M., van der Velden, J., Zacchigna, S., Ghigo, A., Hirsch, E., ... Thum, T. (2020). Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs. Novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 116(11), 1820-1834. https://doi.org/10.1093/cvr/cvaa222